JP2013542190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542190A5 JP2013542190A5 JP2013529652A JP2013529652A JP2013542190A5 JP 2013542190 A5 JP2013542190 A5 JP 2013542190A5 JP 2013529652 A JP2013529652 A JP 2013529652A JP 2013529652 A JP2013529652 A JP 2013529652A JP 2013542190 A5 JP2013542190 A5 JP 2013542190A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- rankl
- breast cancer
- inhibitor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014128 RANK Ligand Human genes 0.000 claims description 13
- 108010025832 RANK Ligand Proteins 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 239000005556 hormone Substances 0.000 claims description 11
- 229940088597 hormone Drugs 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000000186 progesterone Substances 0.000 claims description 4
- 229960003387 progesterone Drugs 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000583 progesterone congener Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 3
- 239000003433 contraceptive agent Substances 0.000 claims 2
- 230000002254 contraceptive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10178346.2 | 2010-09-22 | ||
| EP10178346A EP2433644A1 (en) | 2010-09-22 | 2010-09-22 | Breast cancer therapeutics |
| PCT/EP2011/066511 WO2012038504A2 (en) | 2010-09-22 | 2011-09-22 | Breast cancer therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016212111A Division JP2017039771A (ja) | 2010-09-22 | 2016-10-28 | 乳癌治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542190A JP2013542190A (ja) | 2013-11-21 |
| JP2013542190A5 true JP2013542190A5 (enExample) | 2017-01-12 |
| JP6133778B2 JP6133778B2 (ja) | 2017-05-24 |
Family
ID=43498569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529652A Expired - Fee Related JP6133778B2 (ja) | 2010-09-22 | 2011-09-22 | 乳癌治療剤 |
| JP2016212111A Pending JP2017039771A (ja) | 2010-09-22 | 2016-10-28 | 乳癌治療剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016212111A Pending JP2017039771A (ja) | 2010-09-22 | 2016-10-28 | 乳癌治療剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10143747B2 (enExample) |
| EP (2) | EP2433644A1 (enExample) |
| JP (2) | JP6133778B2 (enExample) |
| KR (1) | KR20130118870A (enExample) |
| CN (1) | CN103384530A (enExample) |
| AU (1) | AU2011306917B2 (enExample) |
| BR (1) | BR112013006673A2 (enExample) |
| CA (1) | CA2811556A1 (enExample) |
| CL (1) | CL2013000801A1 (enExample) |
| IL (1) | IL225442A0 (enExample) |
| MX (1) | MX2013003076A (enExample) |
| NZ (1) | NZ608207A (enExample) |
| PH (1) | PH12013500543A1 (enExample) |
| RU (1) | RU2013118325A (enExample) |
| WO (1) | WO2012038504A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| EP3458090A1 (en) * | 2016-05-19 | 2019-03-27 | Probiocon GmbH | Anti-cancer combination treatment |
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1998028424A2 (en) | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| NZ332995A (en) | 1997-04-15 | 2000-07-28 | Snow Brand Milk Products Co Ltd | A protein which binds to osteoclastogenesis inhibitory factor (OCIF) |
| BR9808545A (pt) | 1997-04-16 | 2000-05-23 | Amgen Inc | ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
| AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6790823B1 (en) * | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| US20040167072A1 (en) | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
| EP1432438A2 (en) | 2001-06-06 | 2004-06-30 | Immunex Corporation | Use of rank antagonists to treat cancer |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| WO2005028633A2 (en) | 2003-09-17 | 2005-03-31 | Isis Pharmaceuticals, Inc. | Modulation of rankl expression |
| WO2005060627A2 (en) | 2003-12-10 | 2005-07-07 | Auxeris Therapeutics, Inc. | Methods of assessing the risk of non-traumatic bone fracture |
| US20080107597A1 (en) | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
| EP1854458A1 (en) | 2006-05-08 | 2007-11-14 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of a compound with RANKL activity |
| TW201019959A (en) | 2008-08-19 | 2010-06-01 | Regeneron Pharma | Human antibodies to human RANKL |
| EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
-
2010
- 2010-09-22 EP EP10178346A patent/EP2433644A1/en not_active Withdrawn
-
2011
- 2011-09-22 PH PH1/2013/500543A patent/PH12013500543A1/en unknown
- 2011-09-22 NZ NZ608207A patent/NZ608207A/en not_active IP Right Cessation
- 2011-09-22 WO PCT/EP2011/066511 patent/WO2012038504A2/en not_active Ceased
- 2011-09-22 CA CA2811556A patent/CA2811556A1/en not_active Abandoned
- 2011-09-22 RU RU2013118325/15A patent/RU2013118325A/ru not_active Application Discontinuation
- 2011-09-22 JP JP2013529652A patent/JP6133778B2/ja not_active Expired - Fee Related
- 2011-09-22 US US13/825,655 patent/US10143747B2/en not_active Expired - Fee Related
- 2011-09-22 CN CN2011800544541A patent/CN103384530A/zh active Pending
- 2011-09-22 AU AU2011306917A patent/AU2011306917B2/en not_active Ceased
- 2011-09-22 EP EP11758242.9A patent/EP2618833B1/en not_active Revoked
- 2011-09-22 MX MX2013003076A patent/MX2013003076A/es unknown
- 2011-09-22 KR KR1020137009817A patent/KR20130118870A/ko not_active Ceased
- 2011-09-22 BR BR112013006673A patent/BR112013006673A2/pt not_active IP Right Cessation
-
2013
- 2013-03-21 IL IL225442A patent/IL225442A0/en unknown
- 2013-03-22 CL CL2013000801A patent/CL2013000801A1/es unknown
-
2016
- 2016-10-28 JP JP2016212111A patent/JP2017039771A/ja active Pending
-
2018
- 2018-10-12 US US16/158,504 patent/US20190030161A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542190A5 (enExample) | ||
| JP2017039771A5 (enExample) | ||
| RU2013118325A (ru) | Лечение рака молочной железы | |
| JP2012515170A5 (enExample) | ||
| JP2013514984A5 (enExample) | ||
| NZ609719A (en) | Pharmaceutical composition | |
| Gao et al. | Lentivirus expressing soluble ST2 alleviates bleomycin-induced pulmonary fibrosis in mice | |
| ES2647542T3 (es) | Una herramienta motorizada de mano | |
| NZ630494A (en) | Administration of lorcaserin to individuals with renal impairment | |
| Chen et al. | Rosai-Dorfman disease successfully treated with thalidomide | |
| JP2020500864A5 (enExample) | ||
| ZA201908404B (en) | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases | |
| JP2012525358A5 (enExample) | ||
| JP2020526507A (ja) | ホットフラッシュの新規処置法 | |
| ES2694582T3 (es) | Combinaciones de inhibidores de aromatasa y antioxidantes | |
| JP2013500324A5 (enExample) | ||
| JP2020536903A5 (enExample) | ||
| Schindler | Hormone replacement therapy (HRT) in women after genital cancer | |
| Sudhakar et al. | An overview on current strategies in breast cancer therapy | |
| WO2014193269A3 (ru) | Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций | |
| US20170035783A1 (en) | Composition for the prevention and therapy of tumor diseases | |
| Bhadra et al. | Role of oral misoprostol for treatment of incomplete abortion | |
| KR102666078B1 (ko) | 항바이러스성 화합물을 포함하는 질내 적용 가능한 장치 | |
| Roeca et al. | Menopause as a Manifestation of Aging | |
| Handelsman et al. | Hormonal male contraception |